Strides Pharma Science to get Rs 147 Crore funding for consumer healthcare business
The agreement also envisages Strides Consumer Pvt Ltd to become a fully owned subsidiary of Strides Global Consumer Healthcare Ltd at a later date, subject to the approval of Reserve Bank of India
"Board of directors have approved the execution by Strides of definitive agreements with funds advised by ICP-III Investment Advisors (ICP) to provide growth capital and focused attention to its Consumer Healthcare Business (CHC)," Strides Pharma Science said in a BSE filing and added that ICP would provide the business with a USD 20 million capital for growth.
The proposed transaction involves subscribing to the equity capital of Strides Consumer Pvt Ltd India and Strides Global Consumer Healthcare Ltd UK, which are currently wholly owned subsidiaries of the company, the filing added.
"The agreement also envisages Strides Consumer Pvt Ltd to become a fully owned subsidiary of Strides Global Consumer Healthcare Ltd at a later date, subject to the approval of Reserve Bank of India, it said.
The Consumer Health Care business had revenues of USD 6.4 million for FY2017-18.
New Delhi: Drug firm Strides Pharma Science has partnered with funds advised by ICP-III Investment Advisors, which will infuse USD 20 million into its consumer healthcare business.
"Board of directors have approved the execution by Strides of definitive agreements with funds advised by ICP-III Investment Advisors (ICP) to provide growth capital and focused attention to its Consumer Healthcare Business (CHC)," Strides Pharma Science said in a BSE filing and added that ICP would provide the business with a USD 20 million capital for growth.
The proposed transaction involves subscribing to the equity capital of Strides Consumer Pvt Ltd India and Strides Global Consumer Healthcare Ltd UK, which are currently wholly owned subsidiaries of the company, the filing added.
"The agreement also envisages Strides Consumer Pvt Ltd to become a fully owned subsidiary of Strides Global Consumer Healthcare Ltd at a later date, subject to the approval of Reserve Bank of India, it said.
The Consumer Health Care business had revenues of USD 6.4 million for FY2017-18.
Next Story
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd